Anavex Life Sciences Corp. — Form 10-K Summary
Reporting period: Fiscal year ended September 30, 2022. Although the request metadata says “2022 Q4,” this filing reports the full fiscal year, with comparisons primarily to fiscal 2021. Anavex is a clinical-stage biopharmaceutical company developing precision-medicine treatments for central nervous system diseases. It has not generated revenue from operations.
Financial performance and liquidity
| Metric | FY2022 | FY2021 |
|---|---|---|
| Operating expenses | $51.0 million | $42.0 million |
| Research and development expense | $37.9 million | $33.0 million |
| General and administrative expense | $13.1 million | $9.0 million |
| Net loss | $48.0 million | $37.9 million |
| Net loss per share, basic and diluted | $0.62 | $0.54 |
| Cash used in operating activities | $24.2 million | $30.4 million |
| Cash and cash equivalents at year-end | $149.2 million | $152.1 million |
| Working capital at year-end | $142.5 million | $150.8 million |
- Revenue and margins: No operating revenue was reported; the company says it does not anticipate revenue until it establishes an alliance or otherwise develops, licenses, or markets products. Profit margins are therefore not meaningful.
- Other income: Net other income was $3.4 million, down from $4.4 million. It included $3.3 million of Australian research and development incentive income and $0.9 million of net interest income, partly offset by a $0.9 million foreign-exchange loss.
- Cash flow and financing: Operating cash use declined year over year, principally due to collection of incentive and tax receivables. Financing activities provided $21.3 million, mainly from at-the-market share sales. The company issued 1.62 million shares through its ATM for gross proceeds of $21.0 million in FY2022.
- Debt and liabilities: The balance sheet lists $10.2 million of current liabilities and no debt line item; the filing does not provide a separate debt balance. Total assets were $152.7 million.
- Stock-based compensation: Expense rose to $18.4 million from $8.2 million, including $11.2 million in R&D and $7.1 million in G&A. The increase materially affected reported expenses and loss.
Material changes and business developments
- Operating expenses increased 21% year over year, while net loss widened by about $10.1 million. The increase in R&D expense reflected higher personnel and stock-based compensation, partly offset by lower external-service costs as certain trial enrollment and manufacturing work eased.
- Cash decreased by $2.9 million during FY2022, compared with a $122.9 million increase in FY2021, when the company raised substantially more capital through equity offerings.
- During FY2022, Anavex reported positive top-line results from the adult Rett syndrome AVATAR trial and the Phase 1 ANAVEX 3-71 trial. It also reported completion of the last patient visit in its Alzheimer’s Phase 2b/3 trial in June 2022; at the filing date, top-line results were expected at the CTAD 2022 conference.
- The pediatric Rett syndrome EXCELLENCE trial continued, with enrollment expanded to sites in Canada and the United Kingdom. The company also described planned advancement of its Parkinson’s disease program and a planned Fragile X clinical program.
Outlook, risks, and unusual items
- Management expects R&D spending to increase as trials and pipeline programs advance and staffing expands. No numerical revenue, earnings, or cash-use guidance is provided.
- Management stated that existing working capital should fund requirements beyond 12 months from issuance of the financial statements. The company nevertheless expects negative cash flows for the foreseeable future, has a $245.6 million accumulated deficit, and may need additional financing; the timing and terms of future funding are uncertain.
- Clinical and regulatory outcomes remain uncertain. Trial results may not be replicated or accepted by regulators, trials may be delayed or require additional work, and product candidates may not be approved or commercialized. Biomarker-based development may also depend on companion diagnostics the company has not developed or commercialized.
- Other notable risks include reliance on Australian R&D incentive refunds, which are subject to eligibility review and audit; foreign-exchange exposure; potential equity dilution; intellectual-property and licensing risks; competition; and evolving drug-pricing and reimbursement regulation. The filing says the Australian R&D incentive claims for 2018–2022 remain open to potential review or audit.
- The company reported no material pending legal proceedings and no material off-balance-sheet arrangements. Auditors issued unqualified opinions on the FY2022 financial statements and internal controls; management also concluded controls were effective. The auditor changed from BDO to Grant Thornton in 2022.
Most important facts for investors to verify
- Review the full Alzheimer’s Phase 2b/3 results and subsequent regulatory feedback, including endpoints, statistical analyses, and biomarker findings.
- Check the status, enrollment, timing, and results of the EXCELLENCE Rett syndrome trial and planned Parkinson’s and Fragile X programs.
- Track cash burn against the $149.2 million year-end cash balance and $142.5 million working capital, and assess management’s stated funding horizon and future financing needs.
- Assess the scale and recurrence of stock-based compensation and the potential dilution from outstanding options, warrants, and future equity issuance.
- Verify the eligibility and collection of Australian R&D incentives, and monitor foreign-exchange effects and any ATO review outcomes.